Latest news with #ProCellEx®
Yahoo
14-05-2025
- Business
- Yahoo
Protalix BioTherapeutics to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference at Nasdaq NYC
CARMIEL, Israel, May 14, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell–based protein expression system, today announced that it will participate in the 3rd Annual H.C. Wainwright BioConnect Investor Conference, taking place on Tuesday, May 20, 2025 at the Nasdaq headquarters in New York City, New York. Eyal Rubin, the Company's Sr. Vice President and Chief Financial Officer, will deliver a company presentation and be available for one-on-one investor meetings throughout the event. Investors interested in scheduling a meeting with the Company's management team should contact their H.C. Wainwright representative or email meetings@ Event Details Conference: 3rd Annual H.C. Wainwright BioConnect Investor Conference Date: Tuesday, May 20, 2025 Location: Nasdaq World Headquarters in New York City (151 W. 43rd Street) Webcast Details A webcast of the live presentation will be available at 4:30 pm, Eastern Daylight Time (EDT), via the following links: Company Link: Webcast Link: About Protalix BioTherapeutics, Inc. Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. It is the first company to gain U.S. Food and Drug Administration (FDA) approval of a protein produced through plant cell-based in suspension expression system. This unique expression system represents a new method for developing recombinant proteins in an industrial-scale manner. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights to taliglucerase alfa for the treatment of Gaucher disease, Protalix's first product manufactured through ProCellEx, excluding in Brazil, where Protalix retains full rights. Protalix's second product, Elfabrio®, was approved by both the FDA and the European Medicines Agency in May 2023. Protalix has partnered with Chiesi Farmaceutici S.p.A. for the global development and commercialization of Elfabrio. Protalix's development pipeline consists of proprietary versions of recombinant therapeutic proteins that target established pharmaceutical markets, including the following product candidates: PRX–115, a plant cell-expressed recombinant PEGylated uricase for the treatment of uncontrolled gout; PRX–119, a plant cell-expressed long acting DNase I for the treatment of NETs-related diseases; and others. Investor Contact: Mike Moyer, Managing DirectorLifeSci Advisors+1-617-308-4306 mmoyer@ Logo: View original content: SOURCE Protalix BioTherapeutics, Inc.
Yahoo
05-05-2025
- Business
- Yahoo
Protalix BioTherapeutics to Announce First Quarter 2025 Financial and Business Results on May 9, 2025
Company to host conference call and webcast at 8:30 a.m. EDT CARMIEL, Israel, May 5, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell–based protein expression system, today announced that it will release its financial results for the quarter ended March 31, 2025 and provide a business and clinical update on May 9, 2025. Management will host a conference call to discuss the financial results and provide an update on recent corporate and regulatory developments. Conference Call Details: Date: Friday, May 9, 2025Time: 8:30 a.m. Eastern Daylight Time (EDT)Toll Free: 1-877-423-9813International: 1-201-689-8573Israeli Toll Free: 1-809-406-247Conference ID: 13753682Call me™: The Call me™ feature allows you to avoid the wait for an operator; you enter your phone number on the platform and the system calls you right away. Webcast Details: Company Link: Link: ID: 13753682 Participants are requested to access the call at least 15 minutes ahead of the conference to register, download and install any necessary audio software. A replay of the call will be available for two weeks on the Events Calendar of the Investors section of the Company's website, at the above link. About Protalix BioTherapeutics, Inc. Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. It is the first company to gain U.S. Food and Drug Administration (FDA) approval of a protein produced through plant cell-based in suspension expression system. This unique expression system represents a new method for developing recombinant proteins in an industrial-scale manner. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights to taliglucerase alfa for the treatment of Gaucher disease, Protalix's first product manufactured through ProCellEx, excluding in Brazil, where Protalix retains full rights. Protalix's second product, Elfabrio®, was approved by both the FDA and the European Medicines Agency in May 2023. Protalix has partnered with Chiesi Farmaceutici S.p.A. for the global development and commercialization of Elfabrio. Protalix's development pipeline consists of proprietary versions of recombinant therapeutic proteins that target established pharmaceutical markets, including the following product candidates: PRX–115, a plant cell-expressed recombinant PEGylated uricase for the treatment of uncontrolled gout; PRX–119, a plant cell-expressed long acting DNase I for the treatment of NETs-related diseases; and others. Investor Contact Mike Moyer, Managing DirectorLifeSci Advisors+1-617-308-4306mmoyer@ Logo - View original content: SOURCE Protalix BioTherapeutics, Inc. Sign in to access your portfolio
Yahoo
24-03-2025
- Business
- Yahoo
Protalix BioTherapeutics to Present at the iAccess Alpha Virtual Best Ideas Spring Conference 2025
CARMIEL, Israel, March 24, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell–based protein expression system, today announced that its management will be participating in the iAccess Alpha Virtual Best Ideas Spring Investment Conference 2025, to be held virtually March 25-26, 2025. iAccess Alpha hosts virtual investor conferences featuring companies recommended by investors. These two-day events include webcast presentations on Day 1, followed by one-on-one meetings between Protalix management and pre-qualified investors on Day 2. For more information about the iAccess Alpha Virtual Best Ideas Spring Investment Conference 2025, or to register and schedule a one-on-one meeting with Protalix, please visit the conference website at: iAccess Alpha Virtual Best Ideas Spring Conference 2025 Live Presentation Date: Tuesday, March 25, 2025 Time: 12:00 p.m. Eastern Daylight Time (EDT) Company Link: Webcast Link: Participants are requested to access the call at least 15 minutes ahead of the conference to register, download and install any necessary audio software. A replay of the call will be available for at least six months on the Events Calendar of the Investors section of Protalix's website, at the above link. About Protalix BioTherapeutics, Inc. Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. It is the first company to gain U.S. Food and Drug Administration (FDA) approval of a protein produced through plant cell-based in suspension expression system. This unique expression system represents a new method for developing recombinant proteins in an industrial-scale manner. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights to taliglucerase alfa for the treatment of Gaucher disease, Protalix's first product manufactured through ProCellEx, excluding in Brazil, where Protalix retains full rights. Protalix's second product, Elfabrio®, was approved by both the FDA and the European Medicines Agency in May 2023. Protalix has partnered with Chiesi Farmaceutici S.p.A. for the global development and commercialization of Elfabrio. Protalix's development pipeline consists of proprietary versions of recombinant therapeutic proteins that target established pharmaceutical markets, including the following product candidates: PRX–115, a plant cell-expressed recombinant PEGylated uricase for the treatment of uncontrolled gout; PRX–119, a plant cell-expressed long acting DNase I for the treatment of NETs-related diseases; and others. Investor Contact Mike Moyer, Managing DirectorLifeSci Advisors+1-617-308-4306mmoyer@ Logo - View original content: SOURCE Protalix BioTherapeutics, Inc. Sign in to access your portfolio
Yahoo
10-03-2025
- Business
- Yahoo
Protalix BioTherapeutics to Announce Fiscal Year 2024 Financial and Business Results on March 17, 2025
Company to host conference call and webcast at 8:30 a.m. EDT CARMIEL, Israel, March 10, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell–based protein expression system, today announced that it will release its financial results for the fiscal year ended December 31, 2024 and provide a business and clinical update on March 17, 2025. Management will host a conference call to discuss the financial results and provide an update on recent corporate and regulatory developments. Conference Call Details: Date: Monday, March 17, 2025 Time: 8:30 a.m. Eastern Daylight Time (EDT) Toll Free: 1-877-423-9813 International: 1-201-689-8573 Israeli Toll Free: 1-809-406-247 Conference ID: 13752080 Call me™: The Call me™ feature allows you to avoid the wait for an operator; you enter your phone number on the platform and the system calls you right away. Webcast Details: Company Link: Webcast Link: Conference ID: 13752080 Participants are requested to access the call at least 15 minutes ahead of the conference to register, download and install any necessary audio software. A replay of the call will be available for two weeks on the Events Calendar of the Investors section of the Company's website, at the above link. About Protalix BioTherapeutics, Inc. Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. It is the first company to gain U.S. Food and Drug Administration (FDA) approval of a protein produced through plant cell-based in suspension expression system. This unique expression system represents a new method for developing recombinant proteins in an industrial-scale manner. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights to taliglucerase alfa for the treatment of Gaucher disease, Protalix's first product manufactured through ProCellEx, excluding in Brazil, where Protalix retains full rights. Protalix's second product, Elfabrio®, was approved by both the FDA and the European Medicines Agency in May 2023. Protalix has partnered with Chiesi Farmaceutici S.p.A. for the global development and commercialization of Elfabrio. Protalix's development pipeline consists of proprietary versions of recombinant therapeutic proteins that target established pharmaceutical markets, including the following product candidates: PRX–115, a plant cell-expressed recombinant PEGylated uricase for the treatment of uncontrolled gout; PRX–119, a plant cell-expressed long acting DNase I for the treatment of NETs-related diseases; and others. Investor Contact Mike Moyer, Managing DirectorLifeSci Advisors+1-617-308-4306mmoyer@ Logo - View original content: SOURCE Protalix BioTherapeutics, Inc.
